Novo Nordisk wins EU approval for Wegovy oral obesity pill
PUBT · 1d ago
Share
Listen to the news
- Novo Nordisk secured European Commission marketing authorization for Wegovy pill, a once-daily oral semaglutide 25 mg for adult weight management.
- The EU also cleared a single-dose pen version of the higher-dose Wegovy 7.2 mg injection for obesity.
- Novo Nordisk cited OASIS 4 trial data showing about 17% mean weight loss for the pill versus 3% for placebo.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novo Nordisk A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607151150OMX_____CNEWS_EN_GNW1001212936_en) on July 15, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved